A Greco

Summary

Affiliation: Istituto Nazionale Tumori
Country: Italy

Publications

  1. ncbi Molecular pathology of differentiated thyroid cancer
    A Greco
    Molecular Mechanisms Unit, Department of Experimental Oncology and Molecular Medicine, IRCCS Foundation, National Tumor Institute, Milan, Italy
    Q J Nucl Med Mol Imaging 53:440-53. 2009
  2. ncbi Rearrangements of NTRK1 gene in papillary thyroid carcinoma
    A Greco
    Department of Experimental Oncology and Laboratory, Operative Unit 3 Molecular Mechanisms of Cancer Growth and Progression, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G Venezian 1, 20133 Milan, Italy
    Mol Cell Endocrinol 321:44-9. 2010
  3. ncbi Growth-inhibitory effect of STI571 on cells transformed by the COL1A1/PDGFB rearrangement
    A Greco
    Department of Experimental Oncology, Operative Unit 3, Istituto Nazionale Tumori, Milan, Italy
    Int J Cancer 92:354-60. 2001
  4. ncbi Biological activity of the thyroid TRK-T3 oncogene requires signalling through Shc
    E Roccato
    Department of Experimental Oncology, Istituto Nazionale Tumori, Via G Venezian 1, 20133 Milan, Italy
    Br J Cancer 87:645-53. 2002
  5. ncbi The DNA rearrangement that generates the TRK-T3 oncogene involves a novel gene on chromosome 3 whose product has a potential coiled-coil domain
    A Greco
    Division of Experimental Oncology A, Istituto Nazionale Tumori, Milan, Italy
    Mol Cell Biol 15:6118-27. 1995
  6. ncbi Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations
    D Ronchetti
    Hematology Service, Department of Medical Sciences, , Ospedale Maggiore IRCCS, Milan, Italy
    Oncogene 20:3553-62. 2001
  7. ncbi TIMP3 regulates migration, invasion and in vivo tumorigenicity of thyroid tumor cells
    M C Anania
    Molecular Mechanisms Unit, IRCCS Foundation Istituto Nazionale dei Tumori, Milan, Italy
    Oncogene 30:3011-23. 2011
  8. ncbi Genomic organization of the human NTRK1 gene
    A Greco
    Division of Experimental Oncology A, Istituto Nazionale Tumori, Milan, Italy
    Oncogene 13:2463-6. 1996
  9. ncbi IGFBP7: an oncosuppressor gene in thyroid carcinogenesis
    M G Vizioli
    Molecular Mechanisms Unit, Department of Experimental Oncology and Molecular Medicine, IRCCS Foundation Istituto Nazionale dei Tumori, Milan, Italy
    Oncogene 29:3835-44. 2010
  10. ncbi Functional analyses and molecular modeling of two c-Kit mutations responsible for imatinib secondary resistance in GIST patients
    E Tamborini
    Experimental Molecular Pathology, Department of Pathology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Oncogene 25:6140-6. 2006

Collaborators

Detail Information

Publications17

  1. ncbi Molecular pathology of differentiated thyroid cancer
    A Greco
    Molecular Mechanisms Unit, Department of Experimental Oncology and Molecular Medicine, IRCCS Foundation, National Tumor Institute, Milan, Italy
    Q J Nucl Med Mol Imaging 53:440-53. 2009
    ..We also report recent findings on gene expression and miRNA profiles of PTC and FTC...
  2. ncbi Rearrangements of NTRK1 gene in papillary thyroid carcinoma
    A Greco
    Department of Experimental Oncology and Laboratory, Operative Unit 3 Molecular Mechanisms of Cancer Growth and Progression, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G Venezian 1, 20133 Milan, Italy
    Mol Cell Endocrinol 321:44-9. 2010
    ....
  3. ncbi Growth-inhibitory effect of STI571 on cells transformed by the COL1A1/PDGFB rearrangement
    A Greco
    Department of Experimental Oncology, Operative Unit 3, Istituto Nazionale Tumori, Milan, Italy
    Int J Cancer 92:354-60. 2001
    ..cytostatic), according to the specificity of the inhibited tyrosine kinase, namely, ABL or PDGFrbeta...
  4. ncbi Biological activity of the thyroid TRK-T3 oncogene requires signalling through Shc
    E Roccato
    Department of Experimental Oncology, Istituto Nazionale Tumori, Via G Venezian 1, 20133 Milan, Italy
    Br J Cancer 87:645-53. 2002
    ..Our results indicate a definitive role of the adaptor protein Shc in TRK-T3 transforming activity...
  5. ncbi The DNA rearrangement that generates the TRK-T3 oncogene involves a novel gene on chromosome 3 whose product has a potential coiled-coil domain
    A Greco
    Division of Experimental Oncology A, Istituto Nazionale Tumori, Milan, Italy
    Mol Cell Biol 15:6118-27. 1995
    ..Molecular analysis of the NTRK1 rearranged fragments indicated that the chromosomal rearrangement is reciprocal and balanced and involves loss of a few nucleotides of germ line sequences...
  6. ncbi Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations
    D Ronchetti
    Hematology Service, Department of Medical Sciences, , Ospedale Maggiore IRCCS, Milan, Italy
    Oncogene 20:3553-62. 2001
    ..Overall, our results support the idea that FGFR3 mutations are graded in terms of their activation capability, thus suggesting that they may play a critical role in the tumor progression of MM patients with t(4;14)...
  7. ncbi TIMP3 regulates migration, invasion and in vivo tumorigenicity of thyroid tumor cells
    M C Anania
    Molecular Mechanisms Unit, IRCCS Foundation Istituto Nazionale dei Tumori, Milan, Italy
    Oncogene 30:3011-23. 2011
    ..Our data indicate that the loss of TIMP3 expression exerts a functional role in the pathogenesis of PTC...
  8. ncbi Genomic organization of the human NTRK1 gene
    A Greco
    Division of Experimental Oncology A, Istituto Nazionale Tumori, Milan, Italy
    Oncogene 13:2463-6. 1996
    ..The sequence of the 5' flanking region indicates a high content in C/G, the absence of TATA box, the presence of several putative binding sites for Sp1, AP1, AP2, AP3, ATF and GCF transcription factors...
  9. ncbi IGFBP7: an oncosuppressor gene in thyroid carcinogenesis
    M G Vizioli
    Molecular Mechanisms Unit, Department of Experimental Oncology and Molecular Medicine, IRCCS Foundation Istituto Nazionale dei Tumori, Milan, Italy
    Oncogene 29:3835-44. 2010
    ..We show that the effects of IGFBP7 are related to apoptosis. Our data suggest that loss of IGFBP7 expression has a functional role in thyroid carcinogenesis, and it may represent a possible basis for therapeutic strategies...
  10. ncbi Functional analyses and molecular modeling of two c-Kit mutations responsible for imatinib secondary resistance in GIST patients
    E Tamborini
    Experimental Molecular Pathology, Department of Pathology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Oncogene 25:6140-6. 2006
    ..The application of molecular simulations allowed us to quantify the interactions between the mutated receptors and imatinib, and to propose a molecular rationale for this type of drug resistance...
  11. ncbi Detection of novel mRNA splice variants of human ING4 tumor suppressor gene
    G Raho
    Department of Experimental Oncology, Operative Unit Molecular Mechanisms of Cancer Growth and Progression, Istituto Nazionale Tumori, Milan, Italy
    Oncogene 26:5247-57. 2007
    ..On the whole our data suggest that alternative splicing could modulate the activity of ING4 tumor suppressor protein...
  12. ncbi The Gly571Arg mutation, associated with the autonomic and sensory disorder congenital insensitivity to pain with anhidrosis, causes the inactivation of the NTRK1/nerve growth factor receptor
    A Greco
    Division of Experimental Oncology A, Istituto Nazionale Tumori, Milan, Italy
    J Cell Physiol 182:127-33. 2000
    ....
  13. ncbi PDGFRalpha, PDGFRbeta and KIT expression/activation in conventional chondrosarcoma
    M S Lagonigro
    Experimental Molecular Pathology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    J Pathol 208:615-23. 2006
    ..The CCS gene profile described here offers a rationale for the use of RTK inhibitors alone or in combination with chemotherapy, and supports further investigation of RTKs and their downstream signals...
  14. ncbi Full activation of MEN2B mutant RET by an additional MEN2A mutation or by ligand GDNF stimulation
    I Bongarzone
    Division of Experimental Oncology A, Istituto Nazionale Tumori, Milan, Italy
    Oncogene 16:2295-301. 1998
    ..These results indicate that the MEN2B phenotype could be influenced by the tissue distribution or concentration of Ret ligand(s)...
  15. ncbi Refined localization of the human TPR gene to chromosome 1q25 by in situ hybridization
    C Miranda
    Division of Experimental Oncology A, Istituto Nazionale Tumori, Milan, Italy
    Genomics 23:714-5. 1994
  16. ncbi TRK-T1 is a novel oncogene formed by the fusion of TPR and TRK genes in human papillary thyroid carcinomas
    A Greco
    Division of Experimental Oncology, Istituto Nazionale Tumori, Milan, Italy
    Oncogene 7:237-42. 1992
    ..TRK-T1 mRNA encodes a protein of 55 kDa reacting with antibodies against the carboxy terminus of the proto-TRK protein. We show also the involvement of TPR in the generation of another TRK-T oncogene...
  17. ncbi Redifferentiating agents in non-radioiodine avid cancer
    E Seregni
    Nuclear Medicine Division, Department of Diagnostic Imaging and Radiotherapy, Fondazione IRCCS National Cancer Institute, Milan, Italy
    Q J Nucl Med Mol Imaging 53:513-9. 2009
    ..This review will discuss the results of the most recent studies on drugs with redifferentiating properties and their application in patients with radioiodine refractory thyroid cancer...